Pharmacogenomic analysis: Correlating molecular substructure classes with microarray gene expression data

被引：81

作者：

Blower P.E. ^{[1
]}

Yang C. ^{[1
]}

Fligner M.A. ^{[2
]}

Verducci J.S. ^{[2
]}

Yu L. ^{[1
]}

Richman S. ^{[3
]}

Weinstein J.N. ^{[3
]}

机构：

[1] Leadscope Inc., Columbus, OH

[2] Department of Statistics, Ohio State University, Columbus, OH

[3] Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD

来源：

The Pharmacogenomics Journal | 2002年 / 2卷 / 4期

关键词：

Molecular class; NCI cell lines; Statistical correlation;

D O I：

10.1038/sj.tpj.6500116

中图分类号：

学科分类号：

摘要：

Genomic studies are producing large databases of molecular information on and other cell and tissue types. Hence, we have the opportunity to link these accumulating data to the drug discovery processes. Our previous efforts at 'information-intensive' molecular pharmacology have focused on the relationship between patterns of gene expression and patterns of drug activity. In the present study, we take the process a step further-relating gene expression patterns, not just to the drugs as entities, but to ∼27 000 substructures and other chemical features within the drugs. This coupling of genomic information with structure-based data mining can be used to identify classes of compounds for which detailed experimental structure-activity studies may be fruitful. Using a systematic substructure analysis coupled with statistical correlations of compound activity with differential gene expression, we have identified two subclasses of quinones whose patterns of activity in the National Cancer Institute's 60-cell line screening panel (NCI-60) correlate strongly with the expression patterns of particular genes: (i) The growth inhibitory patterns of an electron-withdrawing subclass of benzodithiophenedione-containing compounds over the NCI-60 are highly correlated with the expression patterns of Rab7 and other melanoma-specific genes; (ii) the inhibitory patterns of indolonaphthoquinone-containing compounds are highly correlated with the expression patterns of the hematopoietic lineage-specific gene HS1 and other leukemia genes. As illustrated by these proof-of-principle examples, we introduce here a set of conceptual tools and fluent computational methods for projecting directly from gene expression patterns to drug substructures and vice versa. The analysis is presented in terms of the NCI-60 cell lines and microarray- based gene expression patterns, but the concept and methods are broadly applicable to other large-scale pharmacogenomic database sets as well. The approach (SAT for Structure-Activity-Target) provides a systematic way to mine databases for the design of further structure-activity studies, particularly to aid in target and lead identification.

引用

页码：259 / 271

页数：12

共 59 条

[11] Shi L.M., Fan Y., Myers T.G., O'Connor P.M., Paull K.D., Friend S.H., Et al., Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues, J. Chem. Inf. Comput. Sci, 38, pp. 189-199, (1998)
[12] Wu L., Et al., Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening, Cancer Res, 52, pp. 3029-3034, (1992)
[13] Lee J.-S., Et al., Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen, Mol. Phormacol, 46, pp. 627-638, (1994)
[14] Alvarez M., Et al., Generation of a drug resistance profile by quantitation of MDR-I/P-glycoprotein expression in the cell lines of the NCI anticancer drug screen, J. Clin. Invest, 95, pp. 2205-2214, (1995)
[15] Bates S.E., Et al., Molecular targets in the National Cancer Institute drug screen, J. Cancer Res. Clin. Oncol, 121, pp. 495-500, (1995)
[16] Izquierdo M.A., Et al., Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines, Int. J. Cancer, 65, pp. 230-237, (1996)
[17] Koo H.-M., Et al., Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase 11 inhibitors in tumor cell lines harboring activated ras oncogenes, J. Natl. Cancer Inst, 56, pp. 5211-5216, (1996)
[18] O'Connor P.M., Et al., Characterization of the p53-tumor suppressor pathway in cells of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res, 57, pp. 4285-4300, (1997)
[19] Freije J.M., Et al., Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines, Nat. Med, 3, pp. 395-401, (1997)
[20] Wosikowski K., Et al., Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns, J. Natl. Cancer Inst, 89, pp. 1505-1513, (1997)

← 1 2 3 4 5 6 →